Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens
Background: The substance use crisis continues to progress. Medication for Opioid Use Disorder (MOUD) are prescribed to reduce opioid use and related harms; however, many individuals continue to use substances while on treatment. The objective of this study was to describe the temporal and demograph...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Addictive Behaviors Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S235285322400052X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846137664562003968 |
|---|---|
| author | Alannah McEvoy Myanca Rodrigues Brittany B Dennis Jacqueline Hudson David C. Marsh Andrew Worster Lehana Thabane Zainab Samaan |
| author_facet | Alannah McEvoy Myanca Rodrigues Brittany B Dennis Jacqueline Hudson David C. Marsh Andrew Worster Lehana Thabane Zainab Samaan |
| author_sort | Alannah McEvoy |
| collection | DOAJ |
| description | Background: The substance use crisis continues to progress. Medication for Opioid Use Disorder (MOUD) are prescribed to reduce opioid use and related harms; however, many individuals continue to use substances while on treatment. The objective of this study was to describe the temporal and demographic trends of the agreement between self-reported and urine tested substances. Methods: The current study is a retrospective secondary analysis of three phases of a prospective cohort study (Pilot 2011, Genetics of opioid addiction (GENOA) 2013–2017, and Pharmacogenetics of opioid substitution treatment (POST)) 2018–2022) spanning 2011–2022. We compared the self-reported substance use data for opioids, benzodiazepines, amphetamine/methamphetamine (AMP/MET), and cocaine with urine drug results. We compared the positive predictive value (PPV), false omission rate (FOR), sensitivity, and specificity between (i) different drugs; (ii) by sex, and (iii) age group at enrollment in each phase of the study using self-reported substance use at baseline and retrospective electronic health record data on urine drug screenings collected over the same time period. Results: Overall, the average PPV and FOR for any drug across all phases was 80.7 % and 37.9 %, respectively. Sensitivity and specificity were highest for cocaine and lowest for benzodiazepines. We found no specific trend by sex. Lastly, we found a higher sensitivity for opioids and AMP/MET in those under 25 years of age compared to other age groups. PPV increased over time for benzodiazepines, AMP/MET and cocaine and FOR was higher during the pilot and POST phases than the GENOA phase. Conclusion: Our study highlights the unique challenges associated with ascertaining substance use behaviour for individuals receiving MOUD, indicating many patients will accurately report substance use while others do not. It is therefore important to consider the context of the patient, and the type of the co-substance used to select patient-centred testing as indicated. Therefore, the answer to the question of do we need urine drug screen is yes in some cases. |
| format | Article |
| id | doaj-art-8679446c010c46b59c97d3be68d6da1a |
| institution | Kabale University |
| issn | 2352-8532 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Addictive Behaviors Reports |
| spelling | doaj-art-8679446c010c46b59c97d3be68d6da1a2024-12-08T06:11:11ZengElsevierAddictive Behaviors Reports2352-85322025-06-0121100575Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screensAlannah McEvoy0Myanca Rodrigues1Brittany B Dennis2Jacqueline Hudson3David C. Marsh4Andrew Worster5Lehana Thabane6Zainab Samaan7Department of Psychiatry and Behavioural Neurosciences, McMaster University, 100 West 5th St., Hamilton, ON L8N 3K7, CanadaDepartment of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St. W, Hamilton, ON L8S 4L8, CanadaDepartment of Medicine, Division of Social Medicine, University of British Columbia, Vancouver, BC V5Z1M9, Canada; British Columbia Centre on Substance Use, Vancouver, BC V6Z 2A9, CanadaDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, 100 West 5th St., Hamilton, ON L8N 3K7, CanadaNOSM University, 935 Ramsey Lake Rd., Sudbury, ON P3E 2C6, CanadaDepartment of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St. W, Hamilton, ON L8S 4L8, CanadaDepartment of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St. W, Hamilton, ON L8S 4L8, CanadaDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, 100 West 5th St., Hamilton, ON L8N 3K7, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St. W, Hamilton, ON L8S 4L8, Canada; Department of Psychiatry, Queen’s University, Kingston, ON K7L 4X3, Canada; Corresponding author at: Department of Psychiatry, Queen's Univeristy, 752 King St. W, Kingston, ON K7L 4X3, Canada.Background: The substance use crisis continues to progress. Medication for Opioid Use Disorder (MOUD) are prescribed to reduce opioid use and related harms; however, many individuals continue to use substances while on treatment. The objective of this study was to describe the temporal and demographic trends of the agreement between self-reported and urine tested substances. Methods: The current study is a retrospective secondary analysis of three phases of a prospective cohort study (Pilot 2011, Genetics of opioid addiction (GENOA) 2013–2017, and Pharmacogenetics of opioid substitution treatment (POST)) 2018–2022) spanning 2011–2022. We compared the self-reported substance use data for opioids, benzodiazepines, amphetamine/methamphetamine (AMP/MET), and cocaine with urine drug results. We compared the positive predictive value (PPV), false omission rate (FOR), sensitivity, and specificity between (i) different drugs; (ii) by sex, and (iii) age group at enrollment in each phase of the study using self-reported substance use at baseline and retrospective electronic health record data on urine drug screenings collected over the same time period. Results: Overall, the average PPV and FOR for any drug across all phases was 80.7 % and 37.9 %, respectively. Sensitivity and specificity were highest for cocaine and lowest for benzodiazepines. We found no specific trend by sex. Lastly, we found a higher sensitivity for opioids and AMP/MET in those under 25 years of age compared to other age groups. PPV increased over time for benzodiazepines, AMP/MET and cocaine and FOR was higher during the pilot and POST phases than the GENOA phase. Conclusion: Our study highlights the unique challenges associated with ascertaining substance use behaviour for individuals receiving MOUD, indicating many patients will accurately report substance use while others do not. It is therefore important to consider the context of the patient, and the type of the co-substance used to select patient-centred testing as indicated. Therefore, the answer to the question of do we need urine drug screen is yes in some cases.http://www.sciencedirect.com/science/article/pii/S235285322400052XMedication assisted treatmentOpioid use disorderSensitivitySpecificityUrine drug screens |
| spellingShingle | Alannah McEvoy Myanca Rodrigues Brittany B Dennis Jacqueline Hudson David C. Marsh Andrew Worster Lehana Thabane Zainab Samaan Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens Addictive Behaviors Reports Medication assisted treatment Opioid use disorder Sensitivity Specificity Urine drug screens |
| title | Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens |
| title_full | Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens |
| title_fullStr | Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens |
| title_full_unstemmed | Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens |
| title_short | Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens |
| title_sort | do we need urine drug screens in opioid addiction treatment an observational study on self report versus urine drug screens |
| topic | Medication assisted treatment Opioid use disorder Sensitivity Specificity Urine drug screens |
| url | http://www.sciencedirect.com/science/article/pii/S235285322400052X |
| work_keys_str_mv | AT alannahmcevoy doweneedurinedrugscreensinopioidaddictiontreatmentanobservationalstudyonselfreportversusurinedrugscreens AT myancarodrigues doweneedurinedrugscreensinopioidaddictiontreatmentanobservationalstudyonselfreportversusurinedrugscreens AT brittanybdennis doweneedurinedrugscreensinopioidaddictiontreatmentanobservationalstudyonselfreportversusurinedrugscreens AT jacquelinehudson doweneedurinedrugscreensinopioidaddictiontreatmentanobservationalstudyonselfreportversusurinedrugscreens AT davidcmarsh doweneedurinedrugscreensinopioidaddictiontreatmentanobservationalstudyonselfreportversusurinedrugscreens AT andrewworster doweneedurinedrugscreensinopioidaddictiontreatmentanobservationalstudyonselfreportversusurinedrugscreens AT lehanathabane doweneedurinedrugscreensinopioidaddictiontreatmentanobservationalstudyonselfreportversusurinedrugscreens AT zainabsamaan doweneedurinedrugscreensinopioidaddictiontreatmentanobservationalstudyonselfreportversusurinedrugscreens |